Carcinoid Syndrome Management Market Global Report 2026

The carcinoid syndrome management market size has grown strongly in recent years. It will grow from $1.96 billion in 2025 to $2.12 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing diagnosis of neuroendocrine tumors, growing awareness of carcinoid syndrome symptoms, expansion of hospital oncology departments, rising adoption of somatostatin analogues, improving access to cancer diagnostic imaging.

The carcinoid syndrome management market size is expected to see strong growth in the next few years. It will grow to $2.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to advancements in precision oncology and biomarker identification, increasing investment in rare cancer research, rising adoption of targeted and immunotherapies, growing clinical trials for radiopharmaceutical treatments, expansion of personalized treatment protocols in oncology care. Major trends in the forecast period include rising adoption of targeted biologic therapies for symptom control in carcinoid syndrome, increasing use of personalized precision medicine approaches in neuroendocrine tumor management, growing demand for minimally invasive surgical interventions, expansion of radiopharmaceutical therapies for advanced-stage treatment, rising integration of combination therapy approaches for improved patient outcomes.

The increasing cancer burden is expected to propel the growth of the carcinoid syndrome management market going forward. Cancer burden refers to the increasing incidence, prevalence, mortality, and overall health impact of cancer across populations. The increasing cancer burden is driven by the growing aging population, as older individuals face a higher risk of developing cancer due to age-related cellular damage and prolonged exposure to carcinogenic factors. Carcinoid syndrome management helps address the increasing cancer burden by managing debilitating hormone-related symptoms in patients with neuroendocrine tumors, improving patient quality of life, reducing complications, and supporting comprehensive cancer care and long-term treatment outcomes. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, more than 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing cancer burden is driving the growth of the carcinoid syndrome management market.

Key companies operating in the carcinoid syndrome management market are focusing on obtaining regulatory approvals for advanced neuroendocrine tumor therapies to improve disease control, delay tumor progression, and expand treatment options for patients. Regulatory approvals are official authorizations from regulatory agencies confirming that a product, service, or treatment meets required safety, quality, and efficacy standards for commercialization and market use. For example, in March 2025, Exelixis, Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX (cabozantinib) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET). The approval was based on results from the Phase 3 CABINET trial, which demonstrated a statistically significant improvement in progression-free survival compared with placebo, providing a new systemic treatment option for patients with advanced neuroendocrine tumors.

In February 2024, Bristol Myers Squibb Company, a US-based provider of oncology, immunology, cardiovascular, and cell therapy products, acquired RayzeBio, Inc. for approximately $4.1 billion. Through this acquisition, Bristol Myers Squibb sought to strengthen its radiopharmaceutical oncology portfolio and accelerate the development of targeted radiotherapies for solid tumors, including neuroendocrine tumors associated with carcinoid syndrome management. RayzeBio, Inc. is a US-based radiopharmaceutical company specializing in targeted actinium-based therapies for gastroenteropancreatic neuroendocrine tumors and other cancers.

Major companies operating in the carcinoid syndrome management market are Pfizer Inc.; Novartis AG; The Johns Hopkins Health System Corporation; Teva Pharmaceutical Industries Ltd.; Cleveland Clinic Foundation; The Trustees of the University of Pennsylvania; Mayo Clinic; Stanford Health Care; Cedars-Sinai Medical Center; Ipsen Pharma; The University of Texas MD Anderson Cancer Center; Brigham and Women's Hospital; Apollo Hospitals Enterprise Limited; Memorial Sloan Kettering Cancer Center; University of California San Francisco Medical Center; City of Hope National Medical Center; Virginia Mason Franciscan Health; Max Healthcare Institute Limited; Dana-Farber Cancer Institute Inc.; Fred Hutchinson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute Inc.; The Royal Marsden NHS Foundation Trust; Tata Memorial Centre; Oncology Consultants P.A.; Saroj Gupta Cancer Centre and Research Institute.

North America was the largest region in the carcinoid syndrome management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid syndrome management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the carcinoid syndrome management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carcinoid syndrome management market consists of revenues earned by entities by providing services such as diagnostic evaluation, hormone level monitoring, symptom management, and palliative care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid syndrome management market also includes sales of targeted therapy drugs, biomarker testing kits, infusion systems, and supportive care pharmaceuticals. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The carcinoid syndrome management market research report is one of a series of new reports that provides carcinoid syndrome management market statistics, including carcinoid syndrome management industry global market size, regional shares, competitors with a carcinoid syndrome management market share, detailed carcinoid syndrome management market segments, market trends and opportunities, and any further data you may need to thrive in the carcinoid syndrome management industry. This carcinoid syndrome management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.